Cagrilintide vs Survodutide
A side-by-side research comparison of Cagrilintide and Survodutide across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | Cagrilintide | Survodutide |
|---|---|---|
| Full name | Cagrilintide (AM833) | Survodutide (Dual GLP-1/Glucagon Agonist) |
| Category | Weight Management | Weight Management |
| Status | Investigational (Phase III) | Phase 3 Clinical Trial |
| Mechanism | Acts as a dual amylin and calcitonin receptor agonist. It engages satiety centers in the area postrema and hindbrain, reducing food intake and slowing gastric emptying through a pathway distinct from GLP-1. | Activates GLP-1 receptors to reduce appetite while glucagon receptor activation increases hepatic fat oxidation, energy expenditure, and amino acid catabolism. |
| Molecular weight | ~3963 Da | 4,500 Da (approximate) |
| Half-life | ~7-8 days | 5-7 days |
| Bioavailability | High via subcutaneous injection | High (SubQ) |
| Typical dose | 0.3-2.4 mg (titrated) | 0.6-6.0 mg |
| Frequency | Once weekly | Once weekly |
| Route | Subcutaneous injection | Subcutaneous |
Cagrilintide reported benefits
- Appetite suppression and increased satiety
- Meaningful weight loss
- Complements GLP-1 agonists (additive effect)
- Slows gastric emptying
Survodutide reported benefits
- Significant weight loss (up to 19%)
- Liver fat reduction
- Increased energy expenditure
- MASH resolution potential
- Improved lipid profile
Related comparisons
Research and educational reference only. Not medical advice.